Why Insmed Incorporated (INSM) is One of the Best Strong Buy Healthcare Stocks to Invest In

Core Viewpoint - Insmed Incorporated (NASDAQ:INSM) is highlighted as a strong buy healthcare stock, with a recent price target adjustment by Mizuho from $211 to $204 while maintaining an Outperform rating, following positive comments on the Brinsupri launch after the fiscal Q4 report [1][2]. Financial Performance - Insmed reported total revenues of $606.4 million for the full year 2025, with BRINSUPRI revenues at $144.6 million for fiscal Q4 and $172.7 million for the full year 2025 [2]. - ARIKAYCE revenues reached $119.2 million for the quarter and $433.8 million for the full year 2025, reflecting a 19% annual growth and exceeding the upper end of the full year 2025 guidance [2]. - The company anticipates BRINSUPRI revenues to exceed $1 billion for full-year 2026 and has reiterated ARIKAYCE revenue guidance of $450 million to $470 million for the same period [3]. Company Overview - Insmed is a global biopharmaceutical company focused on developing and commercializing therapies for patients with rare diseases, with a pipeline that includes Brensocatib and Treprostinil Palmitil Inhalation Powder (TPIP) [4].